AD/PD 2026 | An overview of current trials investigating novel approaches for the treatment of PD

In the last period of time, we performed trials with drugs which potentially can modify the disease progression. So one of these drugs is prasinezumab, which is a human antibody that can link alpha-synuclein. And we performed two large trials with this drug, and the signals coming from these Phase II trials are encouraging. So the patients had a progression of the disease which is lower compared to placebo. So now the Phase III on a very large population, about 1,000 patients, is going to start and is actually starting in these weeks. But not only prasinezumab, but we also tested other potential symptomatic new treatments. There is a compound by Cerevance, which is in Phase II, very promising, is a dopaminergic modulator. And there are other drugs. For example, as I mentioned before, GBA can actually be modulated and we tested a drug to modulate GBA. There are two trials starting, one trial, sorry, starting at the moment for controlling or inhibiting the hyperactivity of LARK. This one is starting, another one is ending, and this is the LUMA trial which will be finished in the summer with a drug that actually acts on LARK. Other trials are interesting and coming. There is also very good hope for stem cells and there is a trial already started with stem cells and another one is going to start soon. So it’s a very exciting time for research in Parkinson’s disease. We hope that most of the trials will be positive so that the patients could have really a treatment that can delay or halt disease progression.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.